AI-Developed Drug Reaches Human Trials in Just 18 Months, Showcasing Power of AI to Transform Drug Development
• Insilico Medicine published a study showing the first AI-developed drug to reach phase 2 clinical trials, demonstrating AI's potential to accelerate and lower the cost of drug development.
• Insilico's AI tools were used throughout the drug development process, from identifying the target to designing the molecule and running clinical trials.
• The drug, for idiopathic pulmonary fibrosis, took just 18 months to develop compared to the typical 12-20 years, showing the time savings AI can provide.
• Insilico aims to use AI for aging research and extending human longevity, with disease treatment just one application.
• Over 8,000 global energy leaders will meet next week in Houston for CERAWeek 2024 to discuss strategies for delivering economic growth while achieving net zero emissions.